Health
CanSino to start Phase III trial of COVID-19 vaccine in Saudi – The Jakarta Post – Jakarta Post
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China’s CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.
Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China’s CanSino Biologics Inc, a Saudi health ministry spokesman said on Sunday.
Last month, CanSino’s co-founder said the company was in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of the vaccine candidate, Ad5-nCOV.
The vaccine uses a harmless cold virus known as adenovirus type-5 (Ad5) to carry genetic material from the coronavirus into the body…
-
General16 hours agoMontana’s house was gutted by an accidental fire. Then her landlord accused her of starting it
-
Business16 hours agoThe smartest ASX dividend stocks to buy with $5,000 right now
-
Noosa News17 hours agoUniversity of Queensland researchers survey population of endangered White’s Seahorse
-
General17 hours agoNSW to introduce independent regulator following review into early childhood sector